About the Authors
- Lena Muchnik
-
Contributed equally to this work with: Lena Muchnik, Asad Adawi
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Asad Adawi
-
Contributed equally to this work with: Lena Muchnik, Asad Adawi
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Ariel Ohayon
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Shahar Dotan
-
Affiliation Protea Vaccine Technologies and NasVax Ltd., Ness Ziona, Israel
- Itai Malka
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Shalhevet Azriel
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Marilou Shagan
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Maxim Portnoi
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Daniel Kafka
-
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Hannie Nahmani
-
Affiliation The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Angel Porgador
-
Affiliation The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
- Johnatan M. Gershoni
-
Affiliation Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel
- Donald A. Morrison
-
Affiliation Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois, United States of America
- Andrea Mitchell
-
Affiliation School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom
- Michael Tal
-
Affiliation Protea Vaccine Technologies and NasVax Ltd., Ness Ziona, Israel
- Ronald Ellis
-
Affiliation Protea Vaccine Technologies and NasVax Ltd., Ness Ziona, Israel
- Ron Dagan
-
Affiliation Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel
- Yaffa Mizrachi Nebenzahl
-
* E-mail: ymizr@bgu.ac.il
Affiliations Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
Competing Interests
The study and part of the authors were partially funded by a commercial company (Nasvax Ltd./Protea Vaccine Technologies Ltd.) through the BGNegev Biotechnologies which is the BGU industrial liaison. Nasvax Ltd./Protea Vaccine Technologies Ltd. is the employer of authors Shahar Dotan, Michael Tal and Ronald Ellis. The NOX protein discussed in the enclosed manuscript is protected by several pending patents: US WO 03/082183; EP 1490104; PCT WO 2010/029546 A2. The protein vaccine is at an early stage of preclinical studies. There are no marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: YMN RD RE MT DAM JMG AO SD AP. Performed the experiments: LM AO SD SA IM MS MP DK AA HN AP. Analyzed the data: AO SD. Contributed reagents/materials/analysis tools: JMG AM. Wrote the paper: YMN AO SD.